Role of Intravenous Tranexamic acid in decreasing blood loss during transurethral resection of the prostate (TUR-P)
Abstract
INTRODUCTION: Blood loss after transurethral resection of the prostate (TUR -P) is supposed to be related with rise in urinary fibrinolytic activity. Tranexamic acid (TXA) is urokinase activators as well as a potent inhibitor of plasminogen and due to its low molecular weight, the substance excreted unchanged from kidneys into the urinary tract. It can be administered in to the bodyvia oral route, intravenously and topical application through irrigation fluid. We studied the effect of TXA on the amount of blood loss during and after transurethral resection of the prostate (TURP).
OBJECTIVE: To determine the Role of Intravenous Tranexamic acid in decreasing blood loss during transurethral resection of the prostate (TUR -P)
METHODOLOGY: This was randomized controlled trial conducted on 70 patients with serial numbers ending in even numbers were allocated to the treatment group; and those ending in odd numbers were used as controls and received no treatment. The treatment group received 1gram TXA by intravenous infusion prior to start the TUR-P operation, while the control group of patients received no medication. Serum hemoglobin was measured before and after surgery, duration of resection and weight of resected prostatic tissue was recorded.
RESULTS: The mean loss of hemoglobin per gram of resected prostate tissue was 1.25 g in the TXA group and 1.31 g in control group.
CONCLUSION and recommendations:
In our study we appreciate a very little effect of TXA treatment on surgical blood loss and little decrease in volume of irrigating fluid required however no effect seen on the operative time, hospital stay and catheterization period.
KEY WORDS: Role of intervenous tranexamic acid, blood loss, prostate (TUR-P)
References
Meigs JB, Mohr B, Barry MJ, et al: Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clinical Epidemiology 2011; 54: 935-944.
Borboroglu PG, Kane CJ, Ward JF, et al: Immediate and postoperative complications of transurethral prostatectomy in the 1990s. J Urol 1999; 162:1307-1310.
Wendt-Nordahl, G. et al. Improvement in mortality and morbidity in transurethral resection of the prostate over 17 years in a single center. J. Endourol. 21, 1081-1087 (2007).
Uchida, T. et al. Factors influencing morbidity in patients undergoing transurethral resection of the prostate. Urology 53, 98-105 (1999).
Reich, O. et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J. Urol. 180, 246-249 (2008).
Descazeaud, A. et al. Impact of oral anticoagulation on morbidity of transurethral resection of the prostate World J. Urol. 29, 211-216 (2010).
Ahyai, S. A. et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur.Urol. 58, 384-397 (2010)
Sharifi R, Lee M, Ray P, et al: Safety and efficacy of intravesicalaminocaproicacid for bleeding after transurethral resection of prostate. Urology 1986; 27: 214-219.
Miller RA, May MW, Hendry WF, et al: The prevention of secondary haemorrhageafter prostatectomy: the value of antifibrinolytic therapy. Br J Urol1980; 52: 26-28.
Rannikko A, Petas A, Taari K: Tranexamic acid in control of primary hemorrhage during transurethral prostatectomy. Urology 2004; 64: 955-958.
Ekengren JC, Hohn RG: Blood loss during transurethral resection of the prostate as measured with the Hemocue photometer. Scand J UrolNeph19911. Donohue JF, Sharma H, Abraham R, et al: Transurethral prostate resectionand bleeding: a randomized, placebo controlled trial of the role of finasteridefor decreasing operative blood loss. J Urol 2002; 168: 2024-2026.
Hagerty JA, Ginsberg JD, Harmon JD, et al: Pretreatment with finasteridedecreases perioperative bleeding associated with transurethral resection o the prostate. Urology 2000; 55: 684-689.
Sandfeldt L, Bailey DM, Hahn RG: Blood loss during transurethral resection of the prostate after 3 months of treatment with finasteride. Urology 2001; 58: 972-976.
Puchner PJ, Miller MI: The effects of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report. J Urol 1995; 154: 1779-1782.
Hahn RG, and Ekengren JC: Patterns of irrigating fluid absorption during transurethral resection of the prostate as indicated by ethanol. J Urol 1993;149: 502-506.
Berntorp E, Follrud C, Lethagen S: No increased risk of venous thrombosis in women taking tranexamic acid. ThrombHaemost 2001; 86: 714-715.
Ruel MA, Wang F, Bourke ME, et al: Is tranexamic acid safe in patients undergoing coronary endarterectomy? Ann ThoracSurg 2001; 71: 1508-1511.
